Epstein Secrets

largely due to one-offs (trading -6.4%) • Allianz reports net income and operating pre-tax profit inline with prelims on Oct 29 (trading -1.5%) • Lafarge reports EBITDA inline, reiterates FY demand forecast, stock has had good run (trading +0.49%) • Novo Nordisk: FDA panel votes 8-4 to approve new ul

and $0.25. Secondaries (announced/priced): ARRY, PSLV, PVR, LMI LN (rights), PRGX, LGCY, TUMI, PAA IPO's: N/A Key Research: Janney downgrades DIS, Barcap upgrades HFC & downgrades CTXS, Jeff upgrades MNT/MOH Key Research: Nomura upgrades MMM, Raja initiates ABMD (mp) & upgrades CCOI, Piper cuts MDRX

lJpfQp1W8> Airline ownership reform aims to boost investment FT<http://www.ft.com/cms/s/0/1f7d7744-6b73-11e0-a53e-00144feab49a.htmlfaxzzlJpfQp1W8> Lafarge in Clbn gypsum arm sale FT<http://www.ft.com/cms/s/0/0e0d3b70-6b8c-11e0- a53e-00144feab49a.html#axzzlJpfQp1W8> New HSBC chief plans radical shake-up

es at $12.00 Key Research: BMO initiates food/beverage (RAH/DF/MJN/THS/FLO/HAIN), Macquarie initiates US Chemicals (KRA/FMC/ROC/SOA) Key Research: Barcap upgrades NOVN.VX, Baird downgrades PII, Wells downgrades NVE, JPM initiates CRR (ow) & LG FP (neutral) Key Research: GS downgrades SINA (sell) & up

hunts for original web-series programming (WSJ) • Arthur Gallagher (AJG) to buy Wesfarmers Insurance broking unit for —$938 million • Holcim and Lafarge merger of equals (big antitrust concerns) (completion expected H1 2015) • Vivendi: Altice wins bidding contest for SFR phone unit (deal valued at m

(MRD) files $700M IPO through Citi IPO's (lock-up expires): Antero Resources (AR), MacroGenics (MGNX) Western Refining (WNRL) US Key Research: ••• Barcap initiates TRLA (ew), DB upgrades ANNEM & initiates MCHX (buy) ••• GS downgrades CNVR (sell) & initiates AAL (buy) & upgrades ADI, BMO cuts MAT •••

bt, reits outlook (trading +1.3%) • Finmeccanica O1 revs inline, EBITA light, net debt worse, net below, confirms 2013 targets (trading -0.40%) • Lafarge selling 14% stake in Indian subsidiary, raising Eur200mn to fund future Indian growth (trading +1.0%) • RWE O1 op profit inline, net income beats,

(BLUE) files $86.3M through JP Morgan and Bofa, Esperion Therapeutics (ESPR) files for $70M through Credit Suisse and Citigroup US Key Research: • Barcap assumes NYX/AMTD (ew's) & JNS/WDR/ETFC/SCHW (uw's) & reinstates FXCM (ow) • Citi upgrades GPS (buy), GS reinstates SWY (sell) & downgrades GLNG (sel